TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23414763

Group type: EXPERIMENTAL
Intervention: Moisturizing Durable Barrier Cream (MDBC)
Number of subjects: 318

Group type: COMPARATOR
Intervention: 10% Glycerine Cream (Sorbolene)
Number of subjects: 318
Study: 21812264

Group type: EXPERIMENTAL
Intervention: Hualiu recipe (HLR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Guizhi Fuling Capsule
Number of subjects: 110
Study: 19950299

Group type: EXPERIMENTAL
Intervention: 10 mg oral MLN3897 once daily for 12 weeks while continuing to receive MTX once a week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo once daily for 12 weeks while continuing to receive MTX once a week
Number of subjects: 0
Study: 18722214

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A), 25 units injected into each inferior turbinate (total 50 units)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intranasal steroid injection (triamcinolone), 1 cc (20 mg/mL) injected into each inferior turbinate
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (isotonic saline), 1 cc injected into each inferior turbinate
Number of subjects: 39
Study: 15702061

Group type: EXPERIMENTAL
Intervention: Levobupivacaine Group (L) 30 ml of 0.5% levobupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ropivacaine Group (R) 0.75% ropivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Levobupivacaine Group (L)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ropivacaine Group (R)
Number of subjects: 80
Study: 11800193

Group type: EXPERIMENTAL
Intervention: 1-min competing response duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-min competing response duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-s competing response duration
Number of subjects: 0
Study: 9428251

Group type: EXPERIMENTAL
Intervention: Improved management of STDs in intervention communities
Number of subjects: 12537

Group type: COMPARATOR
Intervention: Comparison communities (control)
Number of subjects: 12537

Group type: EXPERIMENTAL
Intervention: Improved management of STDs
Number of subjects: 12537
Study: 8150762

Group type: EXPERIMENTAL
Intervention: Cefepime 2 g i.v. bd
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cefotaxime 2 g i.v. tds
Number of subjects: 55
Study: 3776448

Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 227

Group type: COMPARATOR
Intervention: 70% isopropyl alcohol
Number of subjects: 227
Study: 11795430

Group type: EXPERIMENTAL
Intervention: Bowman-Birk Inhibitor Concentrate (BBIC)
Number of subjects: 0
Study: 30623534

Group type: EXPERIMENTAL
Intervention: Ropivacaine (7.5%, 5 mL)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline (5 mL)
Number of subjects: 46
Study: 29321338

Group type: EXPERIMENTAL
Intervention: Comprehensive training program for emergency unit staff (videos and interactive simulation workshops)
Number of subjects: 691

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 691
Study: 28300812

Group type: EXPERIMENTAL
Intervention: naltrexone 50 mg/day + guanfacine 1 mg/day (N+G)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: placebo naltrexone + guanfacine (NP+G)
Number of subjects: 301

Group type: COMPARATOR
Intervention: naltrexone + placebo guanfacine (N+GP)
Number of subjects: 301

Group type: COMPARATOR
Intervention: double placebo (NP+GP)
Number of subjects: 301
Study: 24231625

Group type: EXPERIMENTAL
Intervention: AESIT at 50% of vLTP1 (18.6 ± 0.7 km/h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: AESIT at 55% of vLTP1 (20.2 ± 0.6 km/h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: AESIT at 60% of vLTP1 (22.3 ± 0.7 km/h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of La at 50% of vLTP1 and La at vLTP1
Number of subjects: 8
Study: 22267280

Group type: EXPERIMENTAL
Intervention: pioglitazone (PIO) 30 mg once daily
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: metformin (MET) 1000 mg twice daily
Number of subjects: 71

Group type: COMPARATOR
Intervention: healthy male controls
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PIO-treated patients
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MET-treated patients
Number of subjects: 71
Study: 20337077

Group type: EXPERIMENTAL
Intervention: One-visit endodontic treatment
Number of subjects: 138

Group type: COMPARATOR
Intervention: Two-visit endodontic treatment (calcium hydroxide as interappointment medicament)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Two-visit endodontic treatment
Number of subjects: 138
Study: 17377528

Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 then 6 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 then 8 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15599127

Group type: EXPERIMENTAL
Intervention: Graded exposure with behavioral experiments
Number of subjects: 6

Group type: COMPARATOR
Intervention: Operant graded activity program
Number of subjects: 6
Study: 11879108

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 gel (100 mg) and condoms
Number of subjects: 1251

Group type: COMPARATOR
Intervention: Condoms only
Number of subjects: 1251
Study: 10434239

Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg twice daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8574711

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily plus Cisapride 20 mg twice daily
Number of subjects: 344

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily alone
Number of subjects: 344
Study: 2186273

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (100 U/kg thrice weekly by intravenous bolus)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 63
Study: 526848

Group type: EXPERIMENTAL
Intervention: Fibroblast interferon (300 u)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30121185

Group type: EXPERIMENTAL
Intervention: Shorter sleep duration
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sleep variables
Number of subjects: 160
Study: 28231304

Group type: EXPERIMENTAL
Intervention: Breakfast high in saturated fat and added sugar (Experimental condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthier breakfast (Control condition)
Number of subjects: 0
Study: 25902327

Group type: EXPERIMENTAL
Intervention: Prophylactic oxytocin infusion at 44.2 IU/h (ED90) in laboring women
Number of subjects: 70

Group type: COMPARATOR
Intervention: Prophylactic oxytocin infusion at 16.2 IU/h (ED90) in nonlaboring women
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Requirement for additional uterotonic agents in laboring women
Number of subjects: 70

Group type: COMPARATOR
Intervention: Requirement for additional uterotonic agents in nonlaboring women
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Incidence of side effects in laboring women
Number of subjects: 70

Group type: COMPARATOR
Intervention: Incidence of side effects in nonlaboring women
Number of subjects: 70
Study: 23222879

Group type: EXPERIMENTAL
Intervention: Auto-servoventilation (ASV) with optimal medical management, n=37
Number of subjects: 72

Group type: COMPARATOR
Intervention: Optimal medical management alone, n=35
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 21340022

Group type: EXPERIMENTAL
Intervention: 8-week low caloric diet-induced weight loss
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Dietary protein level
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Glycemic index (GI) level
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Predictor panel of 15 variables
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Logistic regression model with 9 blood analytes
Number of subjects: 96
Study: 19551860

Group type: EXPERIMENTAL
Intervention: COMT polymorphism (rs4818)
Number of subjects: 4470
Study: 17580734

Group type: EXPERIMENTAL
Intervention: Betaxolol, 20 mg once daily
Number of subjects: 112

Group type: COMPARATOR
Intervention: Metoprolol tartrate, 50 mg twice daily
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 112
Study: 15090020

Group type: EXPERIMENTAL
Intervention: Topical tazarotene 0.1% cream applied BID
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 15
Study: 11764014

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expectancy of alcohol consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no alcohol)
Number of subjects: 0
Study: 9236451

Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia
Number of subjects: 70

Group type: COMPARATOR
Intervention: Blood cardioplegia
Number of subjects: 70
Study: 8431341

Group type: EXPERIMENTAL
Intervention: Intra-articular morphine 5 mg in saline 25 ml
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline 25 ml intra-articularly (Control)
Number of subjects: 20
Study: 3315587

Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC) 30U in 5 minutes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Streptokinase 1,500,000U over 60 minutes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both APSAC and streptokinase
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 25
Study: 31961675

Group type: EXPERIMENTAL
Intervention: Gaussian process models with composite kernels trained on 500 randomly selected ab initio points
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Gaussian process models with composite kernels trained on 1500 potential energy points
Number of subjects: 500
Study: 31464938

Group type: EXPERIMENTAL
Intervention: Auricular point sticking (APS) combined with tranexamic acid, n = 43
Number of subjects: 86

Group type: COMPARATOR
Intervention: Tranexamic acid alone (Control group), n = 43
Number of subjects: 86
Study: 29166890

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) in combination with early motion Physical Therapy (PT) supervised by a physical therapist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early motion Physical Therapy (PT) supervised by a physical therapist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient supervised Physical Therapy (PT) from postoperative day seven till ten
Number of subjects: 0
Study: 26405670

Group type: EXPERIMENTAL
Intervention: Acetic acid irrigation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Topical and systemic antibiotics
Number of subjects: 100
Study: 23955055

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Both counseling and nicotine patch
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Nonadherent to both
Number of subjects: 202
Study: 21484904

Group type: EXPERIMENTAL
Intervention: Sonographic cervical length
Number of subjects: 154

Group type: COMPARATOR
Intervention: Bishop score
Number of subjects: 154
Study: 18280205

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (1000mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17009270

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (15 mg/kg of ideal body weight/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: IV saline (control)
Number of subjects: 27
Study: 14717341

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Amlodipine besilate
Number of subjects: 3200
Study: 10561111

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 22
Study: 8885944

Group type: EXPERIMENTAL
Intervention: Histoacryl Blue (HAB)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 61
Study: 1950033

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lovastatin (all doses)
Number of subjects: 12
Study: 6404914

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31504554

Group type: COMPARATOR
Intervention: GHB (50 mg/kg body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28335841

Group type: EXPERIMENTAL
Intervention: ASV plus optimized medical therapy (OMT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: OMT alone (control)
Number of subjects: 126
Study: 25559612

Group type: EXPERIMENTAL
Intervention: Childhood systolic blood pressure (BP)
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Change in systolic BP from childhood to adulthood
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Childhood systolic BP
Number of subjects: 657
Study: 23444286

Group type: EXPERIMENTAL
Intervention: Doxylamine/pyridoxine delayed-release combination (Diclectin)
Number of subjects: 68
Study: 21148606

Group type: EXPERIMENTAL
Intervention: Ropivacaine via perineural catheter (Group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Saline via perineural catheter (Group B)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral paracetamol (Group C)
Number of subjects: 66
Study: 19293292

Group type: EXPERIMENTAL
Intervention: Exercise and education programme
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard follow-up care
Number of subjects: 44
Study: 17286738

Group type: EXPERIMENTAL
Intervention: Patients confident in managing their health
Number of subjects: 302

Group type: COMPARATOR
Intervention: Patients less confident in managing their health
Number of subjects: 302
Study: 15532347

Group type: EXPERIMENTAL
Intervention: BOOT STRAP intervention
Number of subjects: 801

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 801

Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 801
Study: 12401598

Group type: EXPERIMENTAL
Intervention: FLACC tool for pain assessment
Number of subjects: 79
Study: 10448818

Group type: EXPERIMENTAL
Intervention: Sparing of the superior temporal gyrus
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resection of the superior temporal gyrus
Number of subjects: 30
Study: 7482267

Group type: EXPERIMENTAL
Intervention: Early closure of colostomies
Number of subjects: 38

Group type: COMPARATOR
Intervention: Late closure of colostomies
Number of subjects: 38
Study: 2405737

Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg atropine followed by 0.1 ml/kg 1% lidocaine with 1/200,000 epinephrine (0.5 micrograms/kg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 0.1 ml/kg 1% lidocaine with 1/200,000 epinephrine (0.5 micrograms/kg) without atropine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg atropine followed by 0.1 ml/kg 1% lidocaine without epinephrine
Number of subjects: 65

Group type: COMPARATOR
Intervention: 0.1 ml/kg 1% lidocaine without epinephrine without atropine
Number of subjects: 65
Study: 6776586

Group type: EXPERIMENTAL
Intervention: Diazepam (moderate doses)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 6830407

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 10
Study: 28990404

Group type: EXPERIMENTAL
Intervention: Dynamic, feedback-intensive platform
Number of subjects: 664

Group type: COMPARATOR
Intervention: Static intervention
Number of subjects: 664
Study: 26102639

Group type: EXPERIMENTAL
Intervention: Standardized patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24683578

Group type: COMPARATOR
Intervention: Collagen plug (control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mineralized freeze‐dried bone allograft (FDBA)/β‐tricalcium phosphate (β‐TCP)/collagen plug
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: FDBA/β‐TCP/PRP/collagen plug
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: FDBA/β‐TCP/rhPDGF‐BB/collagen plug
Number of subjects: 41
Study: 22105872

Group type: EXPERIMENTAL
Intervention: Standard-dose IVLE (0.5 g kg(‐1) day(‐1) gradually increased to a maximum of 3.5 g kg(‐1) day(‐1))
Number of subjects: 42

Group type: COMPARATOR
Intervention: Restricted-dose IVLE (1 g kg(‐1) day(‐1))
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Standard-dose IVLE
Number of subjects: 42

Group type: COMPARATOR
Intervention: Restricted-dose IVLE
Number of subjects: 42
Study: 20641098

Group type: EXPERIMENTAL
Intervention: Maternal caffeine intake with fast CYP1A2*1F oxidation status
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Infant slow NAT2 acetylator status
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Mothers consuming caffeine with fast CYP1A2*1F and slow NAT2
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Maternal caffeine and infant CYP1A2*1F fast oxidizer status
Number of subjects: 768
Study: 18540725

Group type: EXPERIMENTAL
Intervention: Thinness expectancy manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducational intervention
Number of subjects: 0
Study: 16032969

Group type: EXPERIMENTAL
Intervention: New divisible formulation of lamotrigine (100 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Plain lamotrigine tablet
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dispersible/chewable lamotrigine tablet
Number of subjects: 48
Study: 14593973

Group type: EXPERIMENTAL
Intervention: Memantine (Ebixa‐‐Lundbeck Ltd)
Number of subjects: 0
Study: 10476345

Group type: EXPERIMENTAL
Intervention: Adrenocortical carcinomas with hypercorticoidism symptoms
Number of subjects: 15

Group type: COMPARATOR
Intervention: Inactive adrenocortical carcinomas
Number of subjects: 15
Study: 7571982

Group type: EXPERIMENTAL
Intervention: Group C (ascites and very low sodium excretion)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 28

Group type: COMPARATOR
Intervention: Group A and B
Number of subjects: 28
Study: 1720118

Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage and physiotherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 61
Study: 6820076

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition regimen with lipid emulsion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Parenteral nutrition regimen without lipid emulsion
Number of subjects: 20
Study: 31151800

Group type: EXPERIMENTAL
Intervention: 0.3 mL of GC1109
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 0.5 mL of GC1109
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 1.0 mL of GC1109
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (normal saline 0.5 mL)
Number of subjects: 104
Study: 28977399

Group type: EXPERIMENTAL
Intervention: 100M allo-hMSCs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200M allo-hMSCs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26242443

Group type: EXPERIMENTAL
Intervention: Continuous diclofenac (150 mg/day)
Number of subjects: 147

Group type: COMPARATOR
Intervention: On-demand diclofenac
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Continuous diclofenac (150 mg/day) in C reactive protein positive or syndesmophytes patients
Number of subjects: 147

Group type: COMPARATOR
Intervention: On-demand diclofenac in C reactive protein positive or syndesmophytes patients
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Continuous diclofenac (150 mg/day) in patients with syndesmophytes
Number of subjects: 147

Group type: COMPARATOR
Intervention: On-demand diclofenac in patients with syndesmophytes
Number of subjects: 147
Study: 25140770

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Montelukast sodium (LTRA)
Number of subjects: 239
Study: 22342508

Group type: EXPERIMENTAL
Intervention: isobaric 2% lidocaine
Number of subjects: 84

Group type: COMPARATOR
Intervention: isobaric 2% mepivacaine
Number of subjects: 84
Study: 19709510

Group type: EXPERIMENTAL
Intervention: 8-mm-tip catheter (Group 1)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Open irrigated-tip catheter (Group 2)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 131
Study: 17601189

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 12
Study: 15240611

Group type: EXPERIMENTAL
Intervention: hPTH (1-34) 400 U daily for 12 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hormone replacement therapy alone
Number of subjects: 51
Study: 11795454

Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (Copaxone)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: IFNbeta-1b (Betaseron)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: IFNbeta-1a (Avonex)
Number of subjects: 156

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 156
Study: 9572541

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate (LE), n=10, instilled one drop into each eye 8 times daily on Days 0 and 1 and four times daily on Days 2 through 42
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo, n=4, instilled one drop into each eye 8 times daily on Days 0 and 1 and four times daily on Days 2 through 42
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (LE and placebo)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate (LE)
Number of subjects: 14
Study: 7599515

Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 2450751

Group type: EXPERIMENTAL
Intervention: Flecainide (150 mg b.i.d.)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propafenone (150 mg t.i.d.)
Number of subjects: 19
Study: 31681981

Group type: COMPARATOR
Intervention: Palliative Care Needs Rounds (monthly hour-long staff-only triage meetings)
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Palliative Care Needs Rounds
Number of subjects: 1700
Study: 30085075

Group type: EXPERIMENTAL
Intervention: Amphotericin B at 100 mg/kg twice daily for 10 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Amphotericin B at 25 mg/kg twice daily for 10 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 36